Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center Study With Up to 5 Years of Follow-up

OBJECTIVE To determine the prevalence and prognostic significance of unrecognized myocardial infarction (MI) by delayed-enhancement MRI (DE-MRI) in asymptomatic patients with diabetes. RESEARCH DESIGN AND METHODS In this prospective, two-center study of asymptomatic patients without known cardiac disease (n = 120), two prespecified cohorts underwent a research MRI: 1) a high-risk group with type 1 diabetes and chronic renal insufficiency (n = 50) and 2) an average-risk group with type 2 diabetes (n = 70). The primary end point was a composite of all-cause mortality and clinical MI. RESULTS Overall, the prevalence of unrecognized MI was 19% by DE-MRI (28% high-risk group and 13% average-risk group) and 5% by electrocardiography. During up to 5 years of follow-up with a total of 460 patient-years of follow-up, the rate of death/MI was markedly higher in patients with diabetes with (vs. without) unrecognized MI (all 44% vs. 7%, high-risk group 43% vs. 6%, and average-risk group 44% vs. 8%; all P < 0.01). After adjustment for Framingham risk score, left ventricular ejection fraction, and diabetes type, the presence of unrecognized MI by DE-MRI conferred an eightfold increase in risk of death/MI (95% CI 3.0–21.1, P < 0.0001). Addition of unrecognized MI to clinical indices significantly improved model discrimination for adverse events (integrated discrimination improvement = 0.156, P = 0.001). CONCLUSIONS Unrecognized MI is prevalent in asymptomatic patients with diabetes without a history of cardiac disease and confers a markedly increased risk of death and clinical MI.

[1]  D. Berman,et al.  Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology. , 2016, JACC. Cardiovascular imaging.

[2]  N. Rofsky,et al.  Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. , 2015, AJR. American journal of roentgenology.

[3]  H. May,et al.  Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. , 2014, JAMA.

[4]  V. Gudnason,et al.  Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. , 2012, JAMA.

[5]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[6]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[7]  M. Budoff,et al.  2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary , 2010 .

[8]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[9]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[10]  E. Barrett,et al.  Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. , 2009, JAMA.

[11]  R. Kim,et al.  Unrecognized Non-Q-Wave Myocardial Infarction: Prevalence and Prognostic Significance in Patients with Suspected Coronary Disease , 2009, PLoS medicine.

[12]  I. Idris,et al.  Is diabetes a coronary risk equivalent? Systematic review and meta‐analysis , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[13]  B. Howard,et al.  Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.

[14]  P. Douglas,et al.  The Imaging Council of the American College of Cardiology. , 2008, JACC. Cardiovascular imaging.

[15]  R. Kwong,et al.  Incidence and Prognostic Implication of Unrecognized Myocardial Scar Characterized by Cardiac Magnetic Resonance in Diabetic Patients Without Clinical Evidence of Myocardial Infarction , 2008, Circulation.

[16]  S. Kalra,et al.  EFFECT OF LOWER TARGETS FOR BLOOD PRESSURE AND LDL CHOLESTEROL ON ATHEROSCLEROSIS IN DIABETES: THE SANDS RANDOMIZED TRIAL , 2008 .

[17]  J. Fleg,et al.  Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. , 2008, JAMA.

[18]  R. Kim,et al.  Performance of Delayed-Enhancement Magnetic Resonance Imaging With Gadoversetamide Contrast for the Detection and Assessment of Myocardial Infarction: An International, Multicenter, Double-Blinded, Randomized Trial , 2008, Circulation.

[19]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[20]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[21]  Fernando Costa,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2007, Diabetes Care.

[22]  Roger B. Davis,et al.  Impact of Unrecognized Myocardial Scar Detected by Cardiac Magnetic Resonance Imaging on Event-Free Survival in Patients Presenting With Signs or Symptoms of Coronary Artery Disease , 2006, Circulation.

[23]  R. Kim,et al.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. , 2005, European heart journal.

[24]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[25]  A. Kadish,et al.  DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.

[26]  A. Marty Minnesota Code Manual of Electrocardiographic Findings , 1983 .

[27]  W. Elliott Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[28]  B. Gersh Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes The DIAD Study: A Randomized Controlled Trial , 2010 .

[29]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.